(3aS,6aR)-3-oxo-hexahydro-furo[3,2-b]pyrrole-4-carboxylic acid 2,2-dimethyl-propyl ester | 927835-29-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧杂环己烷
• 英文名称: (3aS,6aR)-3-oxo-hexahydro-furo[3,2-b]pyrrole-4-carboxylic acid 2,2-dimethyl-propyl ester
• 英文别名: 2,2-dimethylpropyl (3aS,6aR)-3-oxo-3a,5,6,6a-tetrahydrofuro[3,2-b]pyrrole-4-carboxylate
• CAS: 927835-29-8
• 化学式: C₁₂H₁₉NO₄
• 分子量: 241.287
• InChiKey: PMRYPPOSRYHICT-NXEZZACHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Biologically active compounds
  申请人：Quibell Martin

  公开号：US20090131502A1

  公开（公告）日：2009-05-21

  The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease and diseases involving matrix or cartilate degradation.

  本发明涉及式(I)的化合物及其药学上可接受的盐。本发明还涉及含有式(I)的化合物的药物组合物，以及将这些化合物用于治疗从骨质疏松症、帕盖特病、查加斯病、疟疾、牙龈疾病、高钙血症、代谢性骨病和涉及基质或软骨降解的疾病中选择的疾病。
• [EN] BIOLOGICALLY ACTIVE COMPOUNDS<br/>[FR] COMPOSES BIOLOGIQUEMENT ACTIFS
  申请人：AMURA THERAPEUTICS LTD

  公开号：WO2007023281A2

  公开（公告）日：2007-03-01

  [EN] The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease and diseases involving matrix or cartilage degradation.
  [FR] L'invention concerne des composés de formule (I) et des sels de ceux-ci acceptables sur le plan pharmaceutique. L'invention concerne également des compositions pharmaceutiques contenant des composés de formule (I), et l'utilisation de ces composés dans le traitement d'une maladie sélectionnée parmi l'ostéoporose, la maladie de Paget, la maladie de Chagas, la malaria, les maladies gingivales, l'hypercalcémie, la maladie osseuse métabolique et les maladies impliquant la dégradation de matrices ou de cartilages.